Senior Bioinformatics Scientist at Karius

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Healthcare, Life SciencesIndustries

Requirements

Highly curious, creative, and driven by continuous growth and impact on patients’ lives
Expertise in analyzing complex biological datasets, including next-generation sequencing (NGS), metagenomics, transcriptomics, fragmentomics, and single-cell analysis
Ability to create or adapt computational tools and algorithms for biomarker discovery and workflows
Passion for applying technology in novel ways, generating innovative hypotheses, and revealing hidden patterns in data
Strong analytical rigor and grounding in biological rationale
Experience in bioinformatics aspects of cross-functional research projects
Ability to collaborate with scientific, medical, engineering, and commercial teams
Commitment to high standards of data integrity, quality control, validation, and documentation

Responsibilities

Lead data analysis and interpretation of complex biological datasets, including NGS, metagenomics, transcriptomics, fragmentomics, and single-cell analysis
Create or adapt computational tools and algorithms to support biomarker discovery and workflows
Drive bioinformatics aspects of cross-functional research projects in collaboration with scientific and medical leaders, under the guidance of the Director of Computational Biomarker Discovery
Conduct deep exploration of the biological interplay between molecular data and disease conditions, generating insights to advance translational science
Deliver preliminary biological signatures that inform precision medicine applications beyond infectious disease, including autoimmune disorders and oncology
Partner in experimental design by defining analysis plans, selecting appropriate methodologies, and executing computational analyses
Collaborate closely with scientific, medical, engineering, and commercial teams to set company goals and support the development of new partnerships and products
Ensure high standards of data integrity, quality control, and validation, while maintaining rigorous quality documentation and dissemination of scientific findings
Provide clear visibility into areas of ownership and communication

Skills

Bioinformatics

Genomics

Machine Learning

Metagenomics

Computational Biology

Sequencing

Data Analysis

Precision Medicine

Molecular Biology

Karius

Non-invasive diagnostic tests for infections

About Karius

Karius focuses on medical diagnostics for infectious diseases, offering the Karius Test, which detects over 1,000 pathogens from a single blood sample. This non-invasive test is quick and helps clinicians treat hospitalized patients by reducing the need for multiple invasive tests that can delay treatment. The Karius Test utilizes advanced genomics and artificial intelligence to identify microbial cell-free DNA (mcfDNA) in the bloodstream, providing insights into the pathogens responsible for infections. Karius sells these diagnostic tests to healthcare providers, aiming to offer a faster and less invasive alternative to traditional methods, ultimately saving lives and reducing healthcare costs. The company employs proprietary machine learning algorithms to analyze genomic data in real time, continuously updating its reference genome databases to enhance its diagnostic capabilities.

Redwood City, CaliforniaHeadquarters

2014Year Founded

$311.3MTotal Funding

SERIES_CCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Hybrid Work Options

Risks

Competition from AlphaFold 3 could overlap with Karius's genomic insights.

Rapid AI advancements by competitors may outpace Karius's technology.

Reliance on continuous funding rounds indicates potential financial instability.

Differentiation

Karius Test detects over 1,000 pathogens from a single blood sample.

The test uses advanced genomics and AI for rapid, non-invasive diagnostics.

Karius's proprietary algorithms analyze genomic data in real time.

Upsides

Karius secured $100M to expand its test beyond 400 U.S. hospitals.

FDA Breakthrough Device Designation boosts credibility and market potential.

Growing demand for non-invasive diagnostics aligns with Karius's offerings.

Land your dream remote job 3x faster with AI

Try Jobo Free